双鹭药业(002038) - 2017 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2017 was ¥226,512,271.34, a decrease of 12.49% compared to ¥258,842,648.45 in the same period last year[6] - Net profit attributable to shareholders was ¥127,101,509.93, down 14.75% from ¥149,095,308.53 year-on-year[6] - The net profit after deducting non-recurring gains and losses was ¥105,070,177.57, a decline of 36.03% compared to ¥164,249,333.65 in the previous year[6] - The estimated net profit attributable to shareholders for the first half of 2017 is expected to range from 215.52 million to 278.91 million yuan, reflecting a change of -15.00% to 10.00% compared to the same period in 2016[17] Cash Flow - The net cash flow from operating activities increased by 27.42% to ¥84,745,825.37 from ¥66,509,966.95 in the same period last year[6] - Net cash flow from investing activities increased by 132.14%, primarily due to the recovery of principal and increased investment income[15] Assets and Shareholders' Equity - Total assets at the end of the reporting period were ¥4,213,773,458.47, reflecting a 3.25% increase from ¥4,081,272,274.36 at the end of the previous year[6] - Net assets attributable to shareholders rose by 3.32% to ¥4,025,684,426.75 from ¥3,896,512,694.13 at the end of the last year[6] Shareholder Information - The top two shareholders are Xu Mingbo with 22.55% and Xinxiang Bailu Investment Group Co., Ltd. with 21.09%[10] - The total number of ordinary shareholders at the end of the reporting period was 30,346[10] Financial Metrics - The weighted average return on net assets decreased to 3.21% from 4.09% year-on-year, a drop of 0.88%[6] Government Support - The company received government subsidies amounting to ¥4,000,095.68 during the reporting period[7] Changes in Financial Assets and Liabilities - Financial assets measured at fair value increased by 32.19% compared to the end of the previous year, attributed to new stock subscriptions and increases in stock fair value[14] - Accounts receivable decreased by 50.13% compared to the end of the previous year, due to a reduction in transactions settled with receivables[14] - Prepayments increased by 41.15% compared to the end of the previous year, driven by higher prepayments for materials and service fees[14] Expenses and Income - Sales expenses increased by 161.24% year-on-year, primarily due to adjustments in sales strategy and increased costs related to expanding sales channels[15] - Financial expenses rose by 49.68% year-on-year, mainly due to significant fluctuations in exchange gains and losses[15] - Investment income increased by 79.03% year-on-year, resulting from stock gains and the maturity of certain financial products[15]